BIODELIVERY SCIENCES INTL (BDSI) Fundamental Analysis & Valuation

NASDAQ:BDSI

Current stock price

5.59
0 (-0.09%)
At close:
5.6
+0.01 (+0.18%)
After Hours:

This BDSI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. BDSI Profitability Analysis

1.1 Basic Checks

  • BDSI had positive earnings in the past year.
BDSI Yearly Net Income VS EBIT VS OCF VS FCFBDSI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 0 50M -50M

1.2 Ratios

Industry RankSector Rank
ROA 26.14%
ROE 45.18%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BDSI Yearly ROA, ROE, ROICBDSI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 0 100 -100 200 300

1.3 Margins

Industry RankSector Rank
OM 22.27%
PM (TTM) 50.91%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BDSI Yearly Profit, Operating, Gross MarginsBDSI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 0 -100 -200 -300 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. BDSI Health Analysis

2.1 Basic Checks

  • BDSI has less shares outstanding than it did 1 year ago.
  • BDSI has a better debt/assets ratio than last year.
BDSI Yearly Shares OutstandingBDSI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M 100M
BDSI Yearly Total Debt VS Total AssetsBDSI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 100M 200M 300M

2.2 Solvency

  • BDSI has an Altman-Z score of 2.65. This is not the best score and indicates that BDSI is in the grey zone with still only limited risk for bankruptcy at the moment.
  • BDSI has a Debt/Equity ratio of 0.29. This is a healthy value indicating a solid balance between debt and equity.
Industry RankSector Rank
Debt/Equity 0.29
Debt/FCF N/A
Altman-Z 2.65
ROIC/WACCN/A
WACCN/A
BDSI Yearly LT Debt VS Equity VS FCFBDSI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 0 50M -50M 100M 150M

2.3 Liquidity

  • BDSI has a Current Ratio of 2.45. This indicates that BDSI is financially healthy and has no problem in meeting its short term obligations.
  • A Quick Ratio of 2.17 indicates that BDSI has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 2.45
Quick Ratio 2.17
BDSI Yearly Current Assets VS Current LiabilitesBDSI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

9

3. BDSI Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 232.00% over the past year.
  • The Earnings Per Share has been growing by 71.95% on average over the past years. This is a very strong growth
  • BDSI shows a small growth in Revenue. In the last year, the Revenue has grown by 6.54%.
  • The Revenue has been growing by 60.81% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)232%
EPS 3Y37.54%
EPS 5Y71.95%
EPS Q2Q%520%
Revenue 1Y (TTM)6.54%
Revenue growth 3Y44.2%
Revenue growth 5Y60.81%
Sales Q2Q%2.33%

3.2 Future

  • The Earnings Per Share is expected to grow by 21.10% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, BDSI will show a very strong growth in Revenue. The Revenue will grow by 23.45% on average per year.
EPS Next Y-57.48%
EPS Next 2Y-11.49%
EPS Next 3Y8.73%
EPS Next 5Y21.1%
Revenue Next Year22.27%
Revenue Next 2Y24.06%
Revenue Next 3Y23.25%
Revenue Next 5Y23.45%

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
BDSI Yearly Revenue VS EstimatesBDSI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M
BDSI Yearly EPS VS EstimatesBDSI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1 -1

More info and screens

Find the best growth stocksShow best growing peers

2

4. BDSI Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 6.73, the valuation of BDSI can be described as very cheap.
  • BDSI's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.42.
  • Based on the Price/Forward Earnings ratio of 15.84, the valuation of BDSI can be described as correct.
  • The average S&P500 Price/Forward Earnings ratio is at 22.24. BDSI is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 6.73
Fwd PE 15.84
BDSI Price Earnings VS Forward Price EarningsBDSI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 11.15
BDSI Per share dataBDSI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.5 1 1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)0.09
EPS Next 2Y-11.49%
EPS Next 3Y8.73%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BDSI Dividend Analysis

5.1 Amount

  • No dividends for BDSI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

BDSI Fundamentals: All Metrics, Ratios and Statistics

BIODELIVERY SCIENCES INTL

NASDAQ:BDSI (3/22/2022, 8:00:02 PM)

After market: 5.6 +0.01 (+0.18%)

5.59

0 (-0.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-09
Earnings (Next)05-04
Inst Owners0.12%
Inst Owner Change0%
Ins Owners2.45%
Ins Owner Change0%
Market Cap552.29M
Revenue(TTM)166.71M
Net Income(TTM)84.86M
Analysts73.85
Price Target5.48 (-1.97%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 6.73
Fwd PE 15.84
P/S 3.31
P/FCF N/A
P/OCF N/A
P/B 2.94
P/tB N/A
EV/EBITDA 11.15
EPS(TTM)0.83
EY14.85%
EPS(NY)0.35
Fwd EY6.31%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS1.69
BVpS1.9
TBVpSN/A
PEG (NY)N/A
PEG (5Y)0.09
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA 26.14%
ROE 45.18%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM 22.27%
PM (TTM) 50.91%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.51
Health
Industry RankSector Rank
Debt/Equity 0.29
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.45
Quick Ratio 2.17
Altman-Z 2.65
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)232%
EPS 3Y37.54%
EPS 5Y71.95%
EPS Q2Q%520%
EPS Next Y-57.48%
EPS Next 2Y-11.49%
EPS Next 3Y8.73%
EPS Next 5Y21.1%
Revenue 1Y (TTM)6.54%
Revenue growth 3Y44.2%
Revenue growth 5Y60.81%
Sales Q2Q%2.33%
Revenue Next Year22.27%
Revenue Next 2Y24.06%
Revenue Next 3Y23.25%
Revenue Next 5Y23.45%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

BIODELIVERY SCIENCES INTL / BDSI Fundamental Analysis FAQ

What is the ChartMill fundamental rating of BIODELIVERY SCIENCES INTL (BDSI) stock?

ChartMill assigns a fundamental rating of 6 / 10 to BDSI.


Can you provide the valuation status for BIODELIVERY SCIENCES INTL?

ChartMill assigns a valuation rating of 7 / 10 to BIODELIVERY SCIENCES INTL (BDSI). This can be considered as Undervalued.


How profitable is BIODELIVERY SCIENCES INTL (BDSI) stock?

BIODELIVERY SCIENCES INTL (BDSI) has a profitability rating of 8 / 10.


What is the valuation of BIODELIVERY SCIENCES INTL based on its PE and PB ratios?

The Price/Earnings (PE) ratio for BIODELIVERY SCIENCES INTL (BDSI) is 6.73 and the Price/Book (PB) ratio is 2.94.